

**Regierungspraesidium Tuebingen Leitstelle Arzneimittelueberwachung
Baden-Wuerttemberg**

CERTIFICATE NUMBER: **DE_BW_01_GMP_2024_0147**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1,2}

Part 1

Issued following an inspection in accordance with
Art. 63 of Regulation (EU) 536/2014 as amended
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Germany confirms the following:

The manufacturer: **Catalent Germany Schorndorf GmbH**

Site address: **Steinbeisstrasse 1-2, Schorndorf, Baden-Wuerttemberg, 73614, Germany**

OMS Organisation Id. / OMS Location Id.: **ORG-100011845 / LOC-100018835**

Has been inspected under the national inspection programme in connection with manufacturing
authorisation no. **DE_BW_01_MIA_2024_0081** in accordance with Art. 61 of Regulation (EU) No
536/2014 and Art. 40 of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted
on **2024-04-12**, it is considered that it complies with:

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU)
2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product
categories stated in Part 2.³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and
should not be relied upon to reflect the compliance status if more than three years have elapsed since the date
of that inspection. However, this period of validity may be reduced or extended using regulatory risk
management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or
clarifying remarks can be identified through the EudraGMDP website (<http://eudragmdp.ema.europa.eu/>).
This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the
issuing authority.

¹ The certificate referred to in paragraph Art. 15 of Directive 2001/20/EC and Art. 111(5) of Directive 2001/83/EC is also applicable to importers.

² Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products	
Human Investigational Medicinal Products	
1 MANUFACTURING OPERATIONS	
1.1	Sterile products
	<i>1.1.3 Batch certification</i>
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.1 Capsules, hard shell 1.2.1.8 Other solid dosage forms 1.2.1.13 Tablets
	<i>1.2.2 Batch certification</i>
1.3	Biological medicinal products (list of product types)
	<i>1.3.1 Biological medicinal products (list of product types)</i> 1.3.1.5 Biotechnology products 1.3.1.6 Human or animal extracted products
	<i>1.3.2 Batch Certification (list of product types)</i> 1.3.2.2 Immunological products 1.3.2.4 Gene therapy products 1.3.2.5 Biotechnology products 1.3.2.6 Human or animal extracted products
1.5	Packaging
	<i>1.5.1 Primary Packaging</i> 1.5.1.1 Capsules, hard shell 1.5.1.2 Capsules, soft shell 1.5.1.5 Liquids for external use 1.5.1.6 Liquids for internal use 1.5.1.8 Other solid dosage forms 1.5.1.11 Semi-solids 1.5.1.13 Tablets 1.5.1.17 Other non-sterile medicinal products: inhalants.(en)
	<i>1.5.2 Secondary packaging</i>
1.6	Quality control testing
	<i>1.6.3 Chemical/Physical</i>

2 IMPORTATION OF MEDICINAL PRODUCTS	
2.1	Quality control testing of imported medicinal products
	<i>2.1.3 Chemical/Physical</i>
2.2	Batch certification of imported medicinal products
	<i>2.2.1 Sterile products</i> 2.2.1.1 Aseptically prepared 2.2.1.2 Terminally sterilised
	<i>2.2.2 Non-sterile products</i>
	<i>2.2.3 Biological medicinal products</i> 2.2.3.2 Immunological products 2.2.3.4 Gene therapy products 2.2.3.5 Biotechnology products 2.2.3.6 Human or animal extracted products
2.3	Other importation activities
	<i>2.3.1 Site of physical importation</i>
	<i>2.3.2 Importation of intermediate which undergoes further processing</i>

Clarifying remarks (for public users)

For the exact differentiation of authorised activities, discriminated between human medicinal products and investigational medicinal products: see manufacturing authorisation

2024-09-05

Name and signature of the authorised person of the
Competent Authority of

Confidential
Regierungspraesidium Tuebingen Leitstelle
Arzneimittelueberwachung Baden-Wuerttemberg
 Tel: **Confidential**
 Fax: **Confidential**